PARP inhibitors have become the paradigm of drug‐mediated synthetic lethality in HRR‐deficient tumors and have shown clinical efficacy in patients with BRCA1/2‐related breast and ovarian cancers (Fong et al, 2009; Audeh et al, 2010; Tutt et al, 2010; Robson et al, 2017). This evidence concerns the gene BRCA1 and ovarian carcinoma.